The Migraine Association of Ireland and Teva Pharmaceuticals Ireland have created the first ever podcast series produced in Ireland which highlights the real impact on people living with migraine, entitled Beyond Migraine.
Approximately 12- 15% of the population in the Republic of Ireland live with this condition, equating to roughly 500,000 people. Teva conducted national research among people living with migraine in Ireland to explore the impact the disease has on their quality of life, which has informed the content of the Beyond Migraine podcast. It is hoped that this series will improve wider public awareness about the impact on the quality of life that affects people living with migraine.
The series comprises of six episodes, bringing together leading healthcare professionals working in the area of migraine, alongside people living with the condition to address a range of topics including mental health, exercise, understanding triggers, the workplace and how to cope with an unexpected migraine.
All episodes were recorded in March 2021.
The views, information or opinions expressed during the Beyond Migraine podcast series are solely those of the individuals involved and do not represent those of the Migraine Association of Ireland or Teva Pharmaceuticals Ireland. The primary purpose of this podcast series is to educate and inform and is not a substitute for professional diagnosis or treatment.
Reporting of suspected adverse reactions is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. To ensure correct adverse event reporting, healthcare professionals and patients are encouraged to use their national competent authority reporting scheme or you can also report via: www.tevapharm.com/contact-us/
This podcast is supported by funding from Teva Pharmaceuticals Ireland. Speakers have received an honorarium for their contribution to this podcast.